Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H13NO2 |
Molecular Weight | 167.205 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)[C@H](O)C1=CC(O)=CC=C1
InChI
InChIKey=WXFIGDLSSYIKKV-RCOVLWMOSA-N
InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1
Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure, is an adrenergic receptor alpha-1 agonist.. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol is also used in the treatment of priapism, in spite of this application was not approved, it appears to be effective.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9663612 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | METARAMINOL BITARTRATE Approved UseMetaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. |
|||
Palliative | METARAMINOL BITARTRATE Approved UseMetaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. |
|||
Palliative | METARAMINOL BITARTRATE Approved UseMetaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 4 times / hour single, intravenous Dose: 10 mg, 4 times / hour Route: intravenous Route: single Dose: 10 mg, 4 times / hour Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Age Group: 38 years Sex: F Population Size: 1 Sources: |
Disc. AE: Bigeminal rhythm... AEs leading to discontinuation/dose reduction: Bigeminal rhythm (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bigeminal rhythm | 1 patient Disc. AE |
10 mg 4 times / hour single, intravenous Dose: 10 mg, 4 times / hour Route: intravenous Route: single Dose: 10 mg, 4 times / hour Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Age Group: 38 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Augmented natriuretic response to infusion of saline in dogs rendered acutely hypertensive with metaraminol. | 1966 Jul |
|
Myocardial infarction induced by metaraminol bitartrate (aramine). | 1966 Oct |
|
Pulmonary edema: a complication of metaraminol treatment of paroxysmal supraventricular tachycardia. | 1974 May |
|
[Metaraminol--an antidote in corpus cavernosum autoinjection therapy-induced prolonged erection]. | 1986 May |
|
[Epilepsy and hypertensive crisis after intracavernous injection of metaraminol in the treatment of priapism secondary to a papaverine test]. | 1989 May 20 |
|
Post-traumatic priapism treated with metaraminol bitartrate: case report. | 1990 Dec |
|
The effect of intracarotid nonionic contrast media on the blood-brain barrier in acute hypertension. | 1994 Jan |
|
Reversible segmental left-ventricular dysfunction caused by accidental administration of sympathomimetic drug in human. | 1997 Aug 29 |
|
Methanol solvent may cause increased apparent metabolic instability in in vitro assays. | 2001 Feb |
|
Assessment of cardiac sympathetic nerve integrity with positron emission tomography. | 2001 Jul |
|
Randomized controlled study of colloid preload before spinal anaesthesia for caesarean section. | 2001 Nov |
|
Hemodynamic pharmacology of intravenous vasopressors. | 2003 Aug |
|
Drinking attenuates the noradrenaline release in the lateral hypothalamic area induced by angiotensin II activation of the subfornical organ in rats. | 2003 Mar 18 |
|
Prophylactic i.v. metaraminol during spinal anesthesia for elective Cesarean delivery. | 2003 Oct |
|
Use of alpha-agonists for management of anaphylaxis occurring under anaesthesia: case studies and review. | 2004 Dec |
|
A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET. | 2004 Jan |
|
Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. | 2005 Aug |
|
Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. | 2006 |
|
Use of metaraminol in patients with Familial Mediterranean Fever. | 2006 Aug |
|
Planar chromatographic analysis and quantification of short-lived radioactive metabolites from microdialysis fractions. | 2006 Mar 3 |
|
Meningismus after metaraminol administration in a patient with Familial Mediterranean fever. | 2006 Oct |
|
[Effect of fluid resuscitation on adhesion molecule and hemodynamics in patients with severe sepsis]. | 2006 Sep |
|
Amniotic fluid embolism during vaginal delivery under analgesia. Case report. | 2008 Jul-Aug |
|
Is propofol a safe and effective sedative for relocating hip prostheses? | 2009 Jan |
|
Impact of admixture time and diluent order on metaraminol concentration. | 2009 Sep |
|
Vasopressor choice for hypotension in elective Cesarean section: ephedrine or phenylephrine? | 2010 Apr 30 |
|
Molecular imaging of cardiac sympathetic innervation by 11C-mHED and PET: from man to mouse? | 2010 Aug |
|
Clinical evaluation of the flotrac/Vigileo system for continuous cardiac output monitoring in patients undergoing regional anesthesia for elective cesarean section: a pilot study. | 2010 Jun |
|
Adenosine-induced cardiopulmonary arrest in a patient with paroxysmal supraventricular tachycardia--a response. | 2010 May |
Patents
Sample Use Guides
Intramuscular or Subcutaneous Injection: The recommended dose is 2 to 10 mg (0.2 to 1 mL). As with other agents given subcutaneously, only the preferred sites of injection, as set forth in standard texts, should be used.
Intravenous Infusion: The recommended dose is 15 to 100 mg (1.5 to 10 mL) in 500 mL of Sodium Chloride Injection or 5% Dextrose Injection, adjusting the rate of infusion to maintain the blood pressure at the desired level. Higher concentrations of metaraminol, 150 to 500 mg per 500 mL of infusion fluid, have been used.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C01CA09
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
||
|
WHO-VATC |
QC01CA09
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54-49-9
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
5906
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
m7273
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
7229
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
818U2PZ2EH
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
SUB08815MIG
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
C61835
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
D008680
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
METARAMINOL
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
34
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
6805
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID8023268
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
6794
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
7619-17-2
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
DB00610
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
100000081198
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
2716
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
CHEMBL1201319
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY | |||
|
1721
Created by
admin on Fri Dec 15 16:14:41 UTC 2023 , Edited by admin on Fri Dec 15 16:14:41 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)